Brand Name(s): Hycamtin
CAS nº: 123948-87-8
(toh poh TEE kan)
About Topotecan
This new site is dedicated exclusively to topotecan.
It offers you the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about topotecan on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.
This unique site also provides you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total topotecan experience!
Why is this medication prescribed?
Topotecan belongs to the general group of chemotherapy drugs known as topoisomerase inhibitors.
It is used to treat advanced cervical and ovarian cancers as well and small cell lung cancer that has continued to grow after first–line therapy.
Topotecan works by stopping the growth of cancer cells by preventing the development of elements necessary for cell division.
Latest News
BioNumerik begins Phase III ovarian cancer trials on new drug
BioNumerik Pharmaceuticals Inc. on Thursday said the first patient has begun treatment in a global...
[more]GlaxoSmithKline gets EMEA positive opinion for Hycamtin
GlaxoSmithKline, or GSK, said Monday that oral Hycamtin (topotecan hard capsules) has received a...
[more]Hycamtin® Improves Survival in Patients with Relapsed Small Cell Lung Cancer
According to the results of a study published in the Journal of Clinical Oncology, patients with...
[more]Hycamtin(R) (Topotecan HCl) Indication Expanded To Include Treatment of Cervical Cancer in Combination With Chemotherapy
Of more than 40 regimens investigated1 Hycamtin® is the first to provide additional survival...
[more]Committee for Medicinal Products for Human Use Post-authorisation Summary of Positive Opinion for Hycamtin
On 18 October 2006 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive...
[more]